Transgene Biotek (BOM:526139) ROCE %: -0.55% (As of Mar. 2026)


BOM:526139 Transgene Biotek Ltd BOM:526139
47 GF Score
Price ₹3.03
GF Value ₹6.53
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Transgene Biotek ROCE %?

Transgene Biotek BOM:526139 -3.19% 47 ROCE % is -0.55% as of Mar. 2026. GuruFocus rates BOM:526139 with a GF Score™ of 47/100 and a GF Value™ of ₹6.53 (Possible Value Trap). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Transgene Biotek's annualized ROCE % for the quarter that ended in Mar. 2026 was -0.55%.

Transgene Biotek  (BOM:526139) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Transgene Biotek ROCE % Related Terms

Transgene Biotek ROCE % Historical Data

* Premium members only.

The historical data trend for Transgene Biotek's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transgene Biotek ROCE % Chart

Transgene Biotek Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.25 -3.99 -0.39 -0.33 -0.45

Transgene Biotek Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.59 -0.57 -0.38 -0.31 -0.55
BOM:526139
47GF Score
Transgene Biotek Ltd BOM:526139
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Transgene Biotek ROCE % Calculation

Transgene Biotek's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=-5.927/( ( (1440.916 - 127.375) + (1436.551 - 132.56) )/ 2 )
=-5.927/( (1313.541+1303.991)/ 2 )
=-5.927/1308.766
=-0.45 %

Transgene Biotek's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-7.208/( ( (0 - 0) + (1436.551 - 132.56) )/ 1 )
=-7.208/( ( 0 + 1303.991 )/ 1 )
=-7.208/1303.991
=-0.55 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -0.55% mean?
Transgene Biotek (BOM:526139) has a ROCE % of -0.55% as of Mar. 2026.
Is Transgene Biotek's ROCE % too high?
Transgene Biotek's current ROCE % is -0.55%. Overall, Transgene Biotek has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Transgene Biotek's ROCE % compare to VRTX and REGN?
Transgene Biotek's ROCE % of -0.55% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Transgene Biotek's current ROCE % is -0.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgene Biotek stock overvalued right now?
Based on GuruFocus' analysis, Transgene Biotek (BOM:526139) is currently considered Possible Value Trap. The stock's GF Value™ is ₹6.53, compared to a current price of ₹3.03 — trading 53.6% below its estimated fair value. The current ROCE % is -0.55%. Transgene Biotek's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Transgene Biotek (BOM:526139), the current ROCE % is -0.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Transgene Biotek (BOM:526139) Overvalued in 2026?

Based on GuruFocus' analysis, Transgene Biotek stock appears to be undervalued. The current stock price of ₹3.03 is trading 53.6% below its estimated GF Value™ of ₹6.53. GuruFocus considers Transgene Biotek to be Possible Value Trap.

Key valuation signals for BOM:526139:

  • ROCE %: -0.55%
  • GF Value™: ₹6.53 vs. price of ₹3.03 (53.6% below fair value)
  • GF Score™: 47/100 with 4 warning signs

No single metric tells the full story. See the BOM:526139 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Transgene Biotek Business Description

Address Anrich Industrial Area, Plot No. 69 and 70, IDA Bollaram, Sangareddy District, Medak, TG, IND, 502325
Transgene Biotek Ltd is an India-based research and development company. It is engaged in the research and development of molecules and technologies for the production of active pharmaceutical ingredients and other pharmaceutical products. The company is operating only in one segment of Bulk Drugs. Its product portfolio includes TrabiDHA, Tracolimus, and Orlistat. It generates revenue from the sale of goods and services.
47GF Score

Get the complete analysis for BOM:526139

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹3.03
Price
₹6.53
GF Value